Robotic Sleeve Gastrectomy In A Patient Supported With Impella 5.5: Innovation Amongst Advanced Heart Failure Patients
Akanksha Agrawal,Swaroop Bommareddi,Debbie Rinde-Hoffman,Ioana Dumitru
DOI: https://doi.org/10.1016/j.cardfail.2023.10.393
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Obesity and heart failure (HF) are two interrelated epidemics. The treatment of morbidly obese patients with advanced HF and cardiogenic shock is challenging with limited options for definitive therapy. Guidelines recommend against transplantation for patients with BMI (body mass index) >35 kg/m2. The threshold for ventricular assist device (VAD) in a patient with morbid obesity is usually very high, BMI cutoff varying between centers. We present a morbidly obese patient with non-ischemic cardiomyopathy (NICM) admitted with cardiogenic shock, on dual inotropes and impella 5.5, who undergoes robotic sleeve gastrectomy with significant weight reduction, followed by VAD HM3 implantation with intent of bridge to transplant. Case Report A 30-year-old man with NICM, type 2 DM, hypertension, obstructive sleep apnea, morbid obesity (BMI 52) presented with signs and symptoms of acute decompensated HF and cardiogenic shock SCAI C. His RHC demonstrated RA 22, RV 52/11, 22, PA 56/27 (40), PCWP 33, CO 3.2, CI 1.13, SVR 1270, mixed venous 36%. Milrinone was started along with aggressive diuresis, and due to worsening dyspnea, he required VA ECMO cannulation with Impella CP as LV venting strategy. Over next few days, ECMO was decannulated, and impella CP was upgraded to Impella 5.5 via axillary approach. Two weeks later, he underwent robotic sleeve gastrectomy while supported by Impella 5.5 and inotropic therapy. His hemodynamics prior to the procedure were RA 14, PA 56/11 (31), CO 5.2, CI 2, SVR 1192 on milrinone 0.5, dobutamine 5 and impella 5.5 at p8 support. Three weeks post-op, he underwent successful LVAD HM 3 implantation, and was discharged home on post-op day 19 (BMI 39). Weight trends displayed in Figure 1. He continues to lose weight, BMI 34 at 3 month follow up, and he will be listed for transplantation 6 months after LVAD implantation. Conclusion There have been some case reports of bariatric surgery in patients supported already with durable LVADs however this is the first report of using percutaneous temporary mechanical support. Such approach helps HF patients with morbid obesity become more suitable candidates for advanced therapies such as durable LVAD and heart transplantation.
cardiac & cardiovascular systems